Table 1.

Pharmacotherapy at Entry into the Current Study (N = 81)^*

	n	%
High Risk for Weight Gain
Lithium	40	49.4
Divalproex	21	25.9
Olanzapine	12	14.8
Quetiapine	8	9.9
Risperidone	6	7.4
MAOIs (tranylcypromine)	1	1.2
Tricyclic antidepressants (desipramine)	1	1.2
Paroxetine	4	4.9
Insulin	2	2.5
Beta blockers	6	7.4
Lower Risk or No Risk for Weight Gain
Carbamazepine, lamotrigine, topiramate, gabapentin	35	43.2
Aripiprazole, ziprasidone	26	32.1
First generation antipsychotics (perphenazine)	1	1.2
SSRIs (except paroxetine)	20	24.7
Atypical antidepressants (no subject was taking mirtzapine)	17	21.0
Benzodiazepine anxiolytics/hypnotics	28	34.6
Opiates	2	2.5
Stimulants/ADHD medications	4	4.9
Antiparkinsonian medications	5	6.2
Other non-psychotropic medications	49	60.5

MAOI = Monoamine Oxidase Inhibitor; SSRI = Serotonin-Specific Reuptake Inhibitor; ADHD = Attention-Deficit Hyperactivity Disorder.

^*Classification of medications as high risk versus lower risk or no risk was based on data from the following empirical studies and literature reviews: Fava (2000); Malhi et al. (2001); Jallon and Picard (2001); Pischon and Sharma (2001); Vania et al. (2002); Keck and McElroy (2003); Heller (2004). The majority of patients (86.4%; n = 70) were taking ≥ 1 psychotropic medication at entry into the current study; 60.5% (n = 49) also were taking at least one non-psychotropic medication.